Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
$0.38
+2.1%
$0.38
$0.22
$1.30
$8.12M13.64 million shs685,614 shs
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$6.16
+1.0%
$9.34
$0.85
$52.00
$34.74M2.42562,599 shs430,405 shs
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
$0.70
-7.7%
$0.53
$0.32
$2.07
$42.44M2.12848,835 shs376,000 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
$13.00
$10.58M2.352,472 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
+2.15%-3.53%-20.60%-44.90%-61.21%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
+0.98%-14.44%-33.91%+248.02%-83.44%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00%0.00%0.00%0.00%0.00%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
1.8051 of 5 stars
3.52.00.00.01.80.00.6
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.4859 of 5 stars
1.00.00.00.01.80.81.3
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
3.00
Buy$8.002,004.71% Upside
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
2.00
Hold$2.00-67.53% Downside
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00
N/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MGTA, HYPD, PHXM, and ADIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2025
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/A$0.26 per shareN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$44.44K789.44N/AN/A$6.56 per share0.94
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/A$1.23 per shareN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$13.20M-$1.05N/AN/AN/AN/A-191.31%-153.59%N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$49.82M-$58.40N/AN/AN/A-62,238.41%-876.25%-181.67%N/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
-$76.46MN/A0.00N/AN/A-70.88%-57.27%N/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
-$240KN/A0.00N/AN/AN/AN/AN/A

Latest MGTA, HYPD, PHXM, and ADIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$0.22-$0.18+$0.04-$0.18N/AN/A
8/13/2025Q2 2025
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A-$2.50N/A-$2.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/AN/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/A
5.02
5.02
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.20
0.91
0.91
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/A
19.49
19.49
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.23
1.78
N/A

Institutional Ownership

CompanyInstitutional Ownership
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
16.41%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
25.84%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
47.53%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.40%

Insider Ownership

CompanyInsider Ownership
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
4.26%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
10.86%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
15.18%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
1.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
2021.83 million20.90 millionNo Data
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
405.70 million5.08 millionNo Data
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
6760.67 million51.46 millionNot Optionable
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
493.41 million3.35 millionNo Data

Recent News About These Companies

Phaxiam Therapeutics S.A.
PHAXIAM Reports Third-Quarter 2024 Financial Information

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adial Pharmaceuticals stock logo

Adial Pharmaceuticals NASDAQ:ADIL

$0.38 +0.01 (+2.15%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$0.37 -0.01 (-2.66%)
As of 08/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Hyperion DeFi stock logo

Hyperion DeFi NASDAQ:HYPD

$6.16 +0.06 (+0.98%)
As of 08/22/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Magenta Therapeutics stock logo

Magenta Therapeutics NASDAQ:MGTA

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

PHAXIAM Therapeutics stock logo

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)
As of 08/20/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.